To view the PDF file, sign up for a MySharenet subscription.

ASPEN PHARMACARE HOLDINGS LIMITED - Voluntary announcement - Aspen acquires the rights to Hydroxyprogesterone Caproate Injection (HPC)

Release Date: 01/12/2015 09:00
Code(s): APN     PDF:  
Wrap Text
Voluntary announcement - Aspen acquires the rights to Hydroxyprogesterone Caproate Injection (HPC)

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
and its subsidiaries (collectively “Aspen” or “the Group”)


VOLUNTARY ANNOUNCEMENT - ASPEN ACQUIRES THE RIGHTS TO HYDROXYPROGESTERONE
CAPROATE INJECTION (HPC)

Aspen is pleased to announce that Aspen Global Incorporated (“AGI”), a wholly owned subsidiary of
Aspen Holdings, has entered into an agreement with US-based McGuff Pharmaceuticals Inc.
(“McGuff”), a wholly owned subsidiary of McGuff Company, Inc., to acquire the intellectual
property and recently approved Abbreviated New Drug Application in the United States in respect
of the finished dose form of Hydroxyprogesterone Caproate (“HPC”), a product indicated for the
treatment of certain female cancers and hormonal imbalances. McGuff will also manufacture and
supply the HPC injection product to AGI. It is expected that the product will be launched in the
United States during 2016.

The transaction will provide a unique vertical integration opportunity as Aspen currently
manufactures the active pharmaceutical ingredient (“API”) for HPC. The acquisition is in line with
Aspen’s stated intent to develop commercial opportunities in the United States which are aligned to
the intellectual property available within the Group.

Durban
1 December 2015

Sponsor:

Investec Bank Limited

Date: 01/12/2015 09:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story